SCHEMBL12096567

SCHEMBL12096567

CN1c2ccccc2C(C(=O)Oc2ccc(CCC(=O)ON3C(=O)CCC3=O)cc2)c2c(OS(=O)(=O)C(F)(F)F)cccc21

nearest known ligand 0.33

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 11/20 0.33
DRD4 P21917 8/20 0.33
DRD3 P35462 8/20 0.33
DRD1 P21728 6/20 0.33
DRD5 P21918 6/20 0.33
KMT2A Q03164 1/20 0.32
HTR5A P47898 1/20 0.31
MAPK1 P28482 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2225881 0.90 KMT2A (0.30) KMT2A
SCHEMBL4624493 0.88 DRD2 (0.32) DRD2DRD4DRD3DRD1DRD5
Trifluoromethanesulfonic Acid SCHEMBL29065751 0.88 MAPT (0.32) KMT2AMAPK1MAPT
SCHEMBL4532049 0.85 HDAC4 (0.37) KMT2AMAPK1MAPT
SCHEMBL5705543 0.82 DRD2 (0.39) DRD2DRD4DRD3DRD1DRD5
SCHEMBL7787043 0.81 DRD2 (0.38) DRD2DRD4DRD3DRD1DRD5
SCHEMBL8438875 0.80 P2RX7 (0.30)
SCHEMBL1602668 0.78 DRD2 (0.31) DRD2DRD4DRD3DRD1DRD5
SCHEMBL1603303 0.78 DRD2 (0.31) DRD2DRD4DRD3DRD1DRD5
SCHEMBL4802829 0.77 DRD2 (0.35) DRD2DRD4DRD3DRD1DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590976-B2 Detection method using both fluorescence and chemiluminescence labels ACCESS MEDICAL SYSTEMS, LTD. (US) 2026-03-31 US disclosed
US-12416627-B2 Immunoassay with enhanced sensitivity ACCESS MEDICAL SYSTEMS, LTD. (US) 2025-09-16 US disclosed
US-20240302386-A1 DETECTION METHOD USING BOTH FLUORESCENCE AND CHEMILUMINESCENCE LABELS ACCESS MEDICAL SYSTEMS, LTD. 2024-09-12 US disclosed
US-20240272153-A1 METHOD FOR RE-USING A TEST SOLID SURFACE IN A BIOCHEMICAL ASSAY ACCESS MEDICAL SYSTEMS LTD (US) 2024-08-15 US disclosed
CN-118076895-A Method for testing solid surface repeatedly in biochemical determination 万迈医疗仪器有限公司 2024-05-24 CN disclosed
CN-116648458-A Detection methods using both fluorescent and chemiluminescent labels 万迈医疗仪器有限公司 2023-08-25 CN disclosed
US-20210041428-A1 IMMUNOASSAY WITH ENHANCED SENSITIVITY ACCESS MEDICAL SYSTEMS, LTD. 2021-02-11 US disclosed
US-10809251-B2 Immunoassay with enhanced sensitivity ACCESS MEDICAL SYSTEMS, LTD. (US) 2020-10-20 US disclosed
US-10718764-B2 Electrochemiluminescent detection system ACCESS MEDICAL SYSTEMS, LTD. (US) 2020-07-21 US disclosed
US-10451616-B2 Wide range luminescent immunoassays ACCESS MEDICAL SYSTEMS, LTD. (US) 2019-10-22 US disclosed
US-20170052178-A1 ELECTROCHEMILUMINESCENT DETECTION SYSTEM ACCESS MEDICAL SYSTEMS LTD (US) 2017-02-23 US disclosed
US-9568431-B2 Luminescent immunoassays for quantitating analytes having a wide concentration range ACCESS MEDICAL SYSTEMS, LTD. (US) 2017-02-14 US disclosed
US-9435794-B2 Luminescent polymer cyclic amplification ACCESS MEDICAL SYSTEMS, LTD. (US) 2016-09-06 US disclosed
US-20150276724-A1 LUMINESCENT POLYMER CYCLIC AMPLIFICATION ACCESS MEDICAL SYSTEMS, LTD. (US) 2015-10-01 US disclosed
EP-2699906-A2 LUMINESCENT POLYMER CYCLIC AMPLIFICATION Access Medical Systems, Ltd. (US) 2014-02-26 EP disclosed
US-8647889-B2 Luminescent polymer cyclic amplification ACCESS MEDICAL SYSTEMS, LTD. (US) 2014-02-11 US disclosed
US-20130273667-A1 WIDE RANGE LUMINESCENT IMMUNOASSAYS ACCESS MEDICAL SYSTEMS, LTD. (US) 2013-10-17 US disclosed
US-20130071952-A1 LUMINESCENT POLYMER CYCLIC AMPLIFICATION ACCESS MEDICAL SYSTEMS, LTD. (US) 2013-03-21 US disclosed
WO-2012145270-A2 LUMINESCENT POLYMER CYCLIC AMPLIFICATION ACCESS MEDICAL SYSTEMS, LTD. (US) 2012-10-26 WO disclosed
US-20120231459-A1 CHEMILUMINESCENT PROBES FOR MULTIPLEX MOLECULAR QUANTIFICATION AND USES THEREOF GEN-PROBE INCORPORATED (US) 2012-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590976-B2 Detection method using both fluorescence and chemiluminescence labels CD14, FLT4, FLT1 DRD2 3491/4885DRD4 2791/4885DRD3 2926/4885
US-20120231459-A1 CHEMILUMINESCENT PROBES FOR MULTIPLEX MOLECULAR QUANTIFICATION AND USES THEREOF HMBS, NOD1, DCLRE1B DRD2 2584/4885DRD4 1741/4885DRD3 1969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.